PDCD1 and non-small cell lung carcinoma: A systematic review of more than 5,000 patients with advanced NSCLC treated with ICIs revealed that the incidence of irAEs was 16% (3% grade ≥3) for anti–programmed cell death-1 agents and 11% (5% grade ≥3) for anti–PD-L1 agents (7).